Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 2/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6104610 | 0.85 | FPR2 (0.34) | CDK8ALDH1A1PDE10A | |
| SCHEMBL22206931 | 0.82 | PDE10A (0.41) | TYMPPDE10A | |
| SCHEMBL1839601 | 0.77 | TYMP (0.45) | CDK8TYMPKHKMAP4K4POLB | |
| SCHEMBL21136653 | 0.76 | OGA (0.47) | CDK8KHKPIK3CAMTORKDM4E | |
| SCHEMBL6103557 | 0.74 | HRH3 (0.40) | ALDH1A1 | |
| SCHEMBL6103565 | 0.74 | HRH3 (0.40) | ALDH1A1 | |
| SCHEMBL14157431 | 0.74 | ALDH1A1 (0.56) | POLBHTTKMT2AKDM4EALDH1A1 | |
| SCHEMBL22216826 | 0.74 | ALDH1A1 (0.52) | POLBHTTKMT2AKDM4EALDH1A1 | |
| SCHEMBL21135461 | 0.72 | POLB (0.42) | CDK8TYMPKHKMAP4K4POLB | |
| SCHEMBL28152923 | 0.72 | ALDH1A1 (0.59) | POLBHTTKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | UNIVERSITE DE MONTREAL (CA) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | F12, F2, F3 | CDK8 1576/4885TYMP 1450/4885KHK 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.